2026-04-13T02:24:53Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/90632024-12-13T09:05:15Zcom_2072_378070com_2072_378040col_2072_378092

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends Vega Cano, Kreina Sharela Marmolejo Castañeda, David Escriva de Romaní Muñoz, Santiago Ignacio Saura Manich, Cristina Institut Català de la Salut [Vega Cano KS, Marmolejo Castañeda DH] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escrivá-de-Romaní S, Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Medicaments antineoplàstics - Ús terapèutic Anticossos monoclonals - Ús terapèutic Mama - Càncer - Tractament DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos Càncer de mama metastàtic; Teràpies dirigides; Trastuzumab Metastatic breast cancer; Targeted therapies; Trastuzumab Cáncer de mama metastásico; Terapias dirigidas; Trastuzumab Approximately 20% of breast cancers (BC) overexpress human epidermal growth factor receptor 2 (HER2). This subtype of BC is a clinically and biologically heterogeneous disease that was associated with an increased risk for the development of systemic and brain metastases and poor overall survival before anti-HER2 therapies were developed. The standard of care was dual blockade with trastuzumab and pertuzumab as first-line followed by TDM-1 as second-line. However, with the advent of new HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors and antibody- drug conjugates, the clinical outcomes of patients with HER2-positive BC have changed dramatically in recent years, leading to a paradigm shift in the treatment of the disease. Notably, the development of new-generation ADCs has led to unprecedented results compared with T-DM1, currently establishing trastuzumab deruxtecan as a new standard of care in second-line. Despite the widespread availability of HER2-targeted therapies, patients with HER2-positive BC continue to face the challenges of disease progression, treatment resistance, and brain metastases. Response rate and overall life expectancy decrease with each additional line of treatment, and tumor heterogeneity remains an issue. In this review, we update the new-targeted therapeutic options for HER2-positive BC and highlight the future perspectives of treatment in this setting. 2023-02-27T12:06:25Z 2023-02-27T12:06:25Z 2022-12-22 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Vega Cano KS, Marmolejo Castañeda DH, Escrivá-de-Romaní S, Saura C. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. Cancers. 2022 Dec 22;15(1):51. 2072-6694 https://hdl.handle.net/11351/9063 10.3390/cancers15010051 36612047 000909136200001 http://hdl.handle.net/11351/9063 eng Cancers;15(1) https://doi.org/10.3390/cancers15010051 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf MDPI Scientia